Extensive Necrosis as a Prognostic Indicator in mRCC Treated With Deferred Cytoreductive Nephrectomy After ICI Treatment

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Daniel Joyce, MD, of Vanderbilt University Medical Center gives an overview of his study that examined the use of extensive necrosis as a prognostic indicator in patients with mRCC treated with deferred cytoreductive nephrectomy after ICI treatment.

He elaborates on the correlation between the extent of necrosis and long-term outcomes such as OS or PFS, and how the presence of extensive necrosis influences the decision-making process for performing cytoreductive nephrectomy in patients treated with checkpoint inhibitors.